

**STATEMENT ON THE IMPLEMENTATION OF THE MANDATORY  
NON-COMPETITIVE TENDER OFFER**

1. Valeant Pharmaceuticals International, Inc., a company established according to laws of the Canada, with its address registered at 7150 Mississauga Road, Mississauga, Ontario, Canada L5N 8M5, tel. 905 286 3000.

(the Offeror's first and last name, or the corporate name, legal entity code, address, telephone number of the enterprise)

2. AB "SANITAS", registered address at Veiverių st. 134B, Kaunas, Republic of Lithuania, tel. (+370 37) 22 67 25, fax.: (+370 37) 22 36 96.

(the Offeree's name, address, telephone and fax numbers)

3. Decision No. 2K-174 of the Securities Commission to approve the tender offer circular was adopted on 29 August 2011.

(date and number of the Securities Commission's decision to approve the tender offer circular or to amend its terms)

4. The beginning date of the implementation of the tender offer is 2 September 2011, the end date is 15 September 2011.

(dates of the beginning and the end of implementation of the tender offer)

5. The type and class of the securities subject to the tender offer is ordinary registered shares, ISIN code LT0000106171, nominal value is LTL 1 (one litas).

(type, class, ISIN code and nominal value of the securities subject to the tender offer)

6. The number of securities subject to the tender offer is 2,480,895 (two million four hundred eighty thousand eight hundred ninety five), their share in the authorised capital of the Offeree is 7.98% (seven and ninety eight hundredths percent), the share of votes is 7.98% (seven and ninety eight hundredths percent).

(number (units) of securities subject to the tender offer and their share in the Offeree's authorised capital (share capital in case of a bank) and the number of votes (%))

7. The number of the purchased securities of the Offeree is 1,968,631 (one million nine hundred sixty eight thousand six hundred thirty one), their share in the authorised capital of the Offeree is 6.33% (six and thirty three percent), the share of votes is 6.33% (six and thirty three percent).

(number (units) of purchased securities of the Offeree by ISIN codes and their share in the Offeree's authorised capital (share capital in case of a bank) and the number of votes (%))

8. 1,968,631 (one million nine hundred sixty eight thousand six hundred thirty one).

(number (units) of the purchased securities of the Offeree's that have been actually paid for)

On behalf of

Valeant Pharmaceuticals International, Inc.

Executive Vice President



(signature)

Robert Roswell Chai-Onn

Signing date: 20 September 2011